A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-03-18
Adverse events
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-01 (study day 88); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-08 (study day 95); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 140); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 228); relationship: not assessed; serious criteria: hospitalization
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-08 (study day 279); relationship: N; serious criteria: hospitalization
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-30 (study day 421); relationship: not assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-10-21 (study day 565); relationship: N
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-11-26 (study day 601); relationship: N
Data queries
No data queries.